Unknown

Dataset Information

0

Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome.


ABSTRACT: OBJECTIVE:To present long-term respiratory function outcomes from an open-label, multi-center, phase 3 extension study (MOR-005) of elosulfase alfa enzyme replacement therapy (ERT) in patients with Morquio A syndrome. METHODS:In part 1 of MOR-005, patients initially randomized to ERT in the 24-week pivotal study (MOR-004) remained on their regimen (2.0 mg/kg/week or every other week); placebo patients were re-randomized to one of the two regimens. During part 2, all patients received elosulfase alfa 2.0 mg/kg/week. Respiratory function was one of the efficacy endpoints evaluated in MOR-005. Change from MOR-004 baseline to 120 weeks of treatment for the combined population was determined and compared with results from untreated patients from a Morquio A natural history study (MorCAP). RESULTS:Maximum voluntary ventilation (MVV) improved up to week 72 and then stabilized; forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) increased continuously over 120 weeks. Mean increases in the modified per-protocol population was 9.2 % for FVC, 8.8 % for FEV1, and 6.1 % for MVV after 120 weeks. All patients ?14 years showed respiratory improvements, presumably in part related to growth; however, these were greater in treated patients. For those >14 years, treated patients showed improvements, while deterioration occurred in untreated. Altogether, the improvements were significantly greater (P?

SUBMITTER: Hendriksz CJ 

PROVIDER: S-EPMC5065598 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Objective</h4>To present long-term respiratory function outcomes from an open-label, multi-center, phase 3 extension study (MOR-005) of elosulfase alfa enzyme replacement therapy (ERT) in patients with Morquio A syndrome.<h4>Methods</h4>In part 1 of MOR-005, patients initially randomized to ERT in the 24-week pivotal study (MOR-004) remained on their regimen (2.0 mg/kg/week or every other week); placebo patients were re-randomized to one of the two regimens. During part 2, all patients recei  ...[more]

Similar Datasets

| S-EPMC8759989 | biostudies-literature
| S-EPMC5442692 | biostudies-literature
| S-EPMC5298029 | biostudies-literature
| S-EPMC4243006 | biostudies-literature
| S-EPMC4700045 | biostudies-literature
| S-EPMC5604956 | biostudies-literature
| S-EPMC4744659 | biostudies-literature
| S-EPMC7818902 | biostudies-literature
| S-EPMC4206772 | biostudies-literature
| S-EPMC6047108 | biostudies-literature